Open Access iconOpen Access

REVIEW

crossmark

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

WENFEI GE1,#, SHIYAN SONG1,#, XIAOCHEN QI1,#, FENG CHEN1,#, XIANGYU CHE1, YONGHAO SUN1, JIN WANG1, XIAOWEI LI2, NANA LIU3, QIFEI WANG1,*, GUANGZHEN WU1,*

1 Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
2 Department of Urology, The First Hospital of Qinhuangdao, Qinhuangdao, 066000, China
3 Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China

* Corresponding Authors: QIFEI WANG. Email: email; GUANGZHEN WU. Email: email
# The co-first authors: Wenfei Ge, Shiyan Song, Xiaochen Qi and Feng Chen

Oncology Research 2023, 31(3), 255-270. https://doi.org/10.32604/or.2023.027942

Abstract

As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients experience great side effects after immunotherapy, resulting in a survival status far lower than the expected survival rate. Based on these clinical problems, many researchers have been working on the improvement of tumor immunotherapy in recent years and have accumulated numerous research results. We hope to find a more suitable direction for future immunotherapy for ccRCC by combining these results and the latest research progress.

Graphical Abstract

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

Keywords


Cite This Article

APA Style
GE, W., SONG, S., QI, X., CHEN, F., CHE, X. et al. (2023). Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma. Oncology Research, 31(3), 255-270. https://doi.org/10.32604/or.2023.027942
Vancouver Style
GE W, SONG S, QI X, CHEN F, CHE X, SUN Y, et al. Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma. Oncol Res. 2023;31(3):255-270 https://doi.org/10.32604/or.2023.027942
IEEE Style
W. GE et al., "Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma," Oncol. Res., vol. 31, no. 3, pp. 255-270. 2023. https://doi.org/10.32604/or.2023.027942



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 2499

    View

  • 675

    Download

  • 1

    Like

Share Link